New obesity drug boosts GLP-1 weight loss without added side effects A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy without adding side effects in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity
Thus, identifying the molecular substrates underlying these early adaptations is essential for understanding eCB-stress interactions and informing novel therapeutic strategies
Rehman, J., Benet, A
Unfortunately, when the body becomes resistant to this, the health repercussions are telling
N Engl J Med 385(16):14511461 Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
In fact, a shortage of such a vital medication like Ozempic can increase the incidence of hospitalizations and, regrettably, mortality rates, as indicated in a review by the American Journal of Therapeutics